| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Creatine-d5 monohydrate does not directly bind to a specific receptor or enzyme. It functions as a tracer for creatine metabolism. Creatine itself is involved in cellular energy metabolism, particularly in muscles and brain, where it acts as a substrate for creatine kinase to regenerate ATP from ADP.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as tracers for quantification throughout the drug development process. Due to its potential to alter the pharmacokinetic and metabolic characteristics of medications, deuteration has drawn attention[1].
In vitro, creatine-d5 is used to study creatine uptake and metabolism in cell culture models. It is added to culture media (e.g., 10-100 microM), and cells are lysed after various incubation times. The labeled compound and its metabolites (e.g., phosphocreatine, creatinine) are quantified by LC-MS/MS to measure metabolic flux. |
| ln Vivo |
Creatine-d5 monohydrate is not studied for therapeutic in vivo activity. As a tracer, it can be administered to animals (e.g., oral or intravenous administration) to study creatine absorption, distribution, metabolism, and excretion. It is used in preclinical pharmacokinetic studies and metabolic flux analysis.
|
| Enzyme Assay |
For in vitro tracer assays, cells (e.g., C2C12 myotubes or primary neurons) are plated in 6-well plates. Creatine-d5 monohydrate (10-100 microM) is added to culture medium. After 1-24 hours, cells are washed with cold PBS, harvested, and lysed in 80% methanol. The supernatant is analyzed by LC-MS/MS for creatine-d5 and its metabolites (phosphocreatine-d5, creatinine-d5). Data is normalized to protein content.
|
| Cell Assay |
For cell-based assays, cells are incubated with creatine-d5 monohydrate (0-500 microM) for up to 72 hours. Cell viability can be assessed by MTT assay to ensure no cytotoxicity. For uptake studies, cells are lysed at multiple time points. For metabolism studies, medium is collected at various time points to measure creatine-d5 consumption and metabolite production.
|
| Animal Protocol |
For in vivo tracer studies, male C57BL/6 mice or Sprague-Dawley rats (6-8 weeks old, n=3-5 per time point) are administered creatine-d5 monohydrate via oral gavage (e.g., 50-500 mg/kg) or intravenous injection (e.g., 10-50 mg/kg). Blood is collected at 0, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose. Tissues (muscle, brain, liver) are collected at termination. Plasma and tissue homogenates are analyzed by LC-MS/MS.
|
| ADME/Pharmacokinetics |
Creatine-d5 monohydrate (Molecular formula: C4H9D5N3O3·H2O; MW: 167.20 Da) is supplied as a solid (white to off-white powder). Isotopic enrichment: ≥98 atom% D. It is soluble in water and DMSO (e.g., 20 mg/mL in water). It is stored at -20degC, protected from moisture and light. The monohydrate form is the stable crystalline state.
|
| Toxicity/Toxicokinetics |
Creatine-d5 monohydrate is a stable isotope-labeled compound with low toxicity. Creatine monohydrate is generally recognized as safe (GRAS) as a dietary supplement. The deuterium-labeled analog is expected to have similar safety at research doses (e.g., mg/kg levels in animals). Standard laboratory safety practices should be followed. It is for research use only.
|
| References | |
| Additional Infomation |
Creatine-d5 monohydrate (N-methyl-d3; glycine-2,2-d2) is an endogenous metabolite used in stable isotope-resolved metabolomics (SIRM). It serves as an analytical standard for creatine quantification in biological matrices by LC-MS/MS. It is used in studies of muscle and brain bioenergetics and in clinical research on creatine deficiency syndromes. Purity: ≥98% by HPLC.
|
| Molecular Formula |
C4H6D5N3O3
|
|---|---|
| Molecular Weight |
154.18
|
| Related CAS # |
Creatine monohydrate;6020-87-7
|
| Appearance |
White to light yellow solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.4859 mL | 32.4296 mL | 64.8593 mL | |
| 5 mM | 1.2972 mL | 6.4859 mL | 12.9719 mL | |
| 10 mM | 0.6486 mL | 3.2430 mL | 6.4859 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
